Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Protox Therapeutics has received institutional review board approvals to proceed with its Phase IIa clinical trial evaluating PRX302 for the treatment of localized recurrent prostate cancer.
Subscribe to our email newsletter
The company said that the goal of this Phase IIa study will be to optimize dosing in order to fully exploit the therapeutic potential of PRX302, while maintaining its excellent safety profile. Activities associated with patient screening have commenced and the company expects to enroll the first patient in the first quarter of 2008.
Fahar Merchant, president and CEO of Protox, said: “This is the first of three Phase II trials planned to commence this year. The Phase IIa study will enable us to build upon the favorable results from our recently completed Phase I studies and allow us to develop the most effective development strategy to support commercialization of PRX302.”